OmniComm's TrialMaster EDC Solution Selected by Med Device Manufacturer for Phase IV Cardiovascular Device Study
Fort Lauderdale, FL - November 17, 2009
OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, announced today that a leader in the medical device industry has selected OmniComm’s TrialMaster EDC solution for the data capture of a Phase IV cardiovascular study. The 24-months, 7-site study will enroll 100 subjects.
“We look forward to continuing our successful collaboration with this device company,” remarked Stephen Johnson, COO of OmniComm Systems. “Our flagship EDC solution, TrialMaster, has already proven to be an efficient and reliable data capture system for 12 of this customer’s studies during the past 5 years."
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
